Revelation Biosciences Announces Accelerated Gemini Development Plan and Strategic Partnership Initiatives
Revelation Biosciences announced an accelerated development plan for Gemini, replacing its original AKI program with a streamlined Phase 2a study in stage 2/3 acute kidney injury initiating in early 2027 with topline data in late 2027. The redesigned study is expected to cost approximately $7 million versus roughly $60 million under the prior plan — nearly 90% lower — and will be led by investigators at Emory Healthcare and the University of Alabama at Birmingham.
Key figures
- Drug Name
- Gemini (phosphorylated hexaacyl disaccharide, PHAD, TLR4 agonist)
- Phase Of Trial
- Phase 2a
- Tam
- $94 billion
- Study cost new
- $7 million
- Topline data timing
- late 2027
- Cash and equivalents
- $9.1 million
- Study cost prior plan
- $60 million
- Us aki patients annually
- 2300000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.